Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIP chemotherapy for unresectable intrahepatic cholangiocarcinoma
2018-004013-41Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine in intrahepatic cholangiocarcinoma (ICC), sponsored by Erasmus MC. Primary endpoint: One-year overall survival. Started Aug 2019; status: active.
02
Drugs
floxuridine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2018-004013-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004013-41.